Navigation Links
NIH Funds $1M Research at Quest Product Development and University of Colorado for New Digitally-Controlled Endoscopes
Date:8/7/2008

DENVER, Aug. 7 /PRNewswire/ -- Quest Product Development, with partner University of Colorado, has been awarded a $1,000,000 Small Business Technology Transfer grant by the National Institutes of Health (NIH) to continue the development of a next-generation endoscope. MicroFlex technology, derived from aerospace engineering, uses shape metal alloys and micro-actuators that allow active control over the shape of the scope for minimally invasive surgery. Surgeons will guide this ultra-slim 3mm (1/8") diameter scope via a joystick-like control, and can reach previously inaccessible spaces to visualize and diagnose problems. Specialized tools fit through the scope for therapeutic and surgical procedures. Dr. Dale Lawrence, University of Colorado Professor and inventor of the technology, says, "We're excited about the potential of this technology to access small areas of the anatomy."

MicroFlex endoscopes may provide easier out-patient surgery for patients suffering from chronic sinusitis. The sinus application, the first of many potential uses of this technology, was selected due to the prevalence of chronic sinusitis, which effects 33 million Americans, and the challenge of surgery and treatment in these difficult anatomical structures.

Development is being done by Dr. Lawrence's research group at CU Boulder, physicians at the Health Sciences Center and an engineering team from Quest Product Development. A second NIH grant funded research demonstrating that MicroFlex devices can be fabricated as small as 1mm (0.04") diameter, which will allow access deep into areas of the lungs not currently possible, for diagnosis and treatment of lung cancer. Ultimately, MicroFlex technology may provide a useful tool for diagnostic and surgical care for a variety of medical uses including ear-nose-throat, lung, neurosurgery, neonatal and cardiac applications.

MicroFlex is innovative technology with the potential to revolutionize minimally invasive surgerie
'/>"/>

SOURCE Quest Product Development
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Notice of Initial Distribution of Net Settlement Funds
2. NSF Funds New Entrepreneurship Program
3. NIH Funds Vaccine Research for Needle-free and Self-Administered Protection Against Pandemic Influenza
4. XTELL Launches its Commercial Biorepository Services for Research and Pharmaceutical Companies
5. ChanTest Launches New Business to Provide Validated Ion Channel Expressing Cell Lines to the Research Community
6. United BioSource Corporation and CogState Ltd. Form Strategic Partnership to Support Cognitive Assessment in Clinical Research
7. Molecular Biometrics Announces Results of Parkinsons Disease Research and Receipt of Grant From Michael J. Fox Foundation to Advance Diagnostic Technology
8. eResearchTechnology Reports Second Quarter 2008 Results
9. Anacor Pharmaceuticals Appoints Dr. Kurt Jarnagin Vice President of Biological Research
10. Abt Associates Ranked One of Top 20 U.S. Market Research Firms
11. Zenobia Therapeutics, Inc. Receives Michael J. Fox Foundation for Parkinsons Research Award for Work on PD-implicated Protein LRRK2
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... August 3, 2015 E-QURE Corp. ... of its Bio-electrical Signal Therapy device ("BST Device"), a ... hard to heal chronic wounds, today announced that the ... an Israeli distributor specializing in medical devices, for the ... Chemipal is a 70 years old, sales, marketing and ...
(Date:8/3/2015)... Aug. 3, 2015 /PRNewswire/ - RepliCel Life Sciences Inc. (TSX.V: ... on the development of autologous cell therapies, announced today that ... the InvestMNT conference held in Minneapolis, Minnesota ... time. Hall,s presentation will highlight RepliCel,s 18-month milestones including CE ... Europe , clinical data from both RCT-01 (tendon) ...
(Date:7/31/2015)... , ... July 31, 2015 , ... ... competitive market analysis and premium industry insights on the global resorcinol industry. The ... a collective study of vivid market scenarios and analysis of primary and secondary ...
(Date:7/30/2015)... ... , ... Ralco is honored to announce that it is the primary sponsor ... August 5-9 in Marshall. The Ralco Enrichment Center is an interactive experience where the ... their daily lives. This unique exhibit also features a birthing center for fair goers ...
Breaking Biology Technology:E-QURE Corp Signs Second Distribution Agreement in Israel 2E-QURE Corp Signs Second Distribution Agreement in Israel 3RepliCel Presenting at InvestMNT Investor Conference in Minneapolis 2Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 2Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 3Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 4Ralco Announces Primary Sponsorship of Ralco Enrichment Center at Lyon County Fair 2
... NEEDHAM, Mass., Jan. 22 Hospitals and ... procedures that allow,construction projects to take place ... free white paper that addresses these challenges ... The white paper, titled "Infection Control ...
... Barr Pharmaceuticals,Inc. (NYSE: BRL ) today ... with,Ortho Women,s Health & Urology, Division of ... settle the,outstanding patent litigation involving Ortho Women,s ... LO (norgestimate/ethinyl,estradiol). The United States District Court ...
... Speed in Reaching First Clinical Milestone Validates Approach, ... today,announced the successful completion of its first clinical ... for SYN-111,(rufinamide), a sodium channel blocker. Rufinamide was ... by Eisai in Europe as a,drug to treat ...
Cached Biology Technology:White Paper Details Infection Control Challenges Hospitals Must Address During Construction 2Barr and Ortho Women's Health & Urology in Discussions to Settle ORTHO TRI-CYCLEN(R) LO Patent Litigation 2Barr and Ortho Women's Health & Urology in Discussions to Settle ORTHO TRI-CYCLEN(R) LO Patent Litigation 3Synosia Announces Encouraging Results of Proof-of-Concept Clinical Trial for Epilepsy Drug rufinamide as a Treatment for Mood Disorders 2Synosia Announces Encouraging Results of Proof-of-Concept Clinical Trial for Epilepsy Drug rufinamide as a Treatment for Mood Disorders 3
(Date:7/8/2015)... SAN DIEGO , July 8, 2015 /PRNewswire/ ... of cell-free molecular diagnostics, today announced the launch ... of the Company,s Precision Cancer Monitoring℠ (PCM) technology ... patients receiving one or a combination of the ... and Opdivo® (nivolumab), a PD-1 inhibitor. The 50-patient ...
(Date:7/7/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company") ... announces a revised version of one of its first 30 second ... CNBC in New York , Chicago ... San Francisco metro areas.    , , ... replace all the cards in your wallet and keep your identity ...
(Date:6/30/2015)... 30, 2015 To bolster its efforts and commitment ... announced today the addition of two new team members. ... advisor and David Raviv will act as head ... Corp.,s commitment to providing the most secure solutions for the ... co-founded Layer 7 Technologies, a provider of security and management ...
Breaking Biology News(10 mins):Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 3HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3
... altered osteoporosis drug may be useful in fighting malaria, researchers ... other parasitic protozoa, the drug readily crosses into the red ... The drug works at very low concentrations with no observed ... Proceedings of the National Academy of Sciences . ...
... A group of scientists from across the world have come ... into how fructose causes obesity and metabolic syndrome, more commonly ... performed in lab animals, researchers found that fructose can be ... One form appears to be responsible for causing how fructose ...
... CA--A study of the tropical coral reef system along the ... could threaten the long-term health of the reefs. Led by ... was published in the journal Coral Reefs (online ... loss of predatory fish leads to a cascade of effects ...
Cached Biology News:Modified bone drug kills malaria parasite in mice 2Research offers insight to how fructose causes obesity and other illness 2Coral reef study traces indirect effects of overfishing 2
Rabbit polyclonal to Kallikrein 1 ( Abpromise for all tested applications). Antigen: Full length native kallikrein from tissue (Human) Entrez Gene ID: 3816 Swiss Protein ID: P06870...
Biotin d anti-mouse Tim-1...
... Kir2.1 protein. The epitope is specific ... in any other known protein.,SPECIES REACTIVITIES: ... in rabbit, bovine, porcine and guinea ... rat and mouse (17/19 residues) and ...
Mouse monoclonal [J53] to Thyroid Hormone Receptor beta 1 ( Abpromise for all tested applications). entrezGeneID: 7068 SwissProtID: P10828...
Biology Products: